Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase NA 1

Status

Recruiting 2Completed 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Solid Tumors 1CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × zolbetuximab × Clear all
NCT01630083 2025-06-15

FAST

Astellas Pharma Inc

Phase 2 Completed
252 enrolled
Gastrointestinal

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction

NCT01197885 2025-06-13

Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer

Astellas Pharma Inc

Phase 2 Completed
54 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡